The post-launch phase is critical for demonstrating sustained value, safety, and effectiveness across diverse patient populations.  

Real-world evidence (RWE) plays an important role in addressing post-launch needs by providing insights into long-term safety, adherence, treatment patterns, and comparative effectiveness. RWE helps ensure a drug continues to deliver value across its lifecycle to patients, providers, and payers. 

Key topics

In this webinar, the speakers will discuss: 

• Post-launch needs in the drug lifecycle 

• The role of RWE  

• Cytel’s capabilities in supporting post-launch evidence generation 

Speakers

• Anupama Vasudevan, BDS, MPH, PhD, Senior Director RWE, US
• Leila Karimi, MD, PhD, Director RWE, Netherlands